Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(7): 381-387
DOI: 10.1055/s-2005-865716
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Quantitative Evaluation of a Monoclonal Antibody and its Fragment as Potential Markers for Pancreatic Beta Cell Mass

C. S. Hampe1 , A. R. Wallen1 , M. Schlosser2 , M. Ziegler3 , I. R. Sweet1
  • 1Department of Medicine, University of Washington, Seattle, Washington, USA
  • 2Institute of Pathophysiology, Ernst Moritz Arndt University of Greifswald, Karlsburg, Germany
  • 3Institute of Diabetes „Gerhardt Katsch“, Karlsburg, Germany
Further Information

Publication History

Received: October 13, 2004 First decision: February 2, 2005

Accepted: April 28, 2005

Publication Date:
18 July 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Antibodies, due to their high specificities and retention, represent potential beta cell imaging agents, however their slow clearance from the blood may preclude their use. Antibody fragments (Fabs) have much higher clearance and if they can be made with similar binding characteristics, would be more efficacious agents. An existing beta cell specific antibody (K14D10) and its Fab were evaluated with a previously developed screening assay. The Fab and the intact immunoglobulin (IgG) had similar affinities (6 - 20 nM), binding sites (300 000 - 700 000 sites/cell), and binding kinetics (t1/2 = 8 - 18 minutes) for beta cells. However, the cellular specificity was far below the estimated requisite values needed to overcome the very low beta cell mass in the pancreas. The Fab cleared the blood twice as fast as the IgG, but did not preferentially accumulate into pancreas. Thus, generation of Fabs from IgGs with high beta cell binding and blood clearance appears feasible, but in order for molecules to be useful for tracking beta cell mass, antibodies of greater cellular specificity will have to be used.

Key words

Beta cell mass - monoclonal antibodies - Fab - PET

References

  • 1 Adams G P, Schier R. Generating improved single-chain Fv molecules for tumor targeting.  J Immunol Methods. 1999;  231 249-260
    CrossrefPubMedGoogle Scholar
  • 2 Asfari M, Janjic D, Meda P, Li G, Halban P A, Wollheim C B. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines.  Endocrinology. 1992;  130 167-178
    CrossrefPubMedGoogle Scholar
  • 3 Bazin-Redureau M I, Renard C B, Scherrmann J M. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat.  J Pharm Pharmacol. 1997;  49 277-281
    PubMedGoogle Scholar
  • 4 Boyle C C, Paine A J, Mather S J. The mechanism of hepatic uptake of a radiolabelled monoclonal antibody.  Int J Cancer. 1992;  50 912-917
    PubMedGoogle Scholar
  • 5 Brinkmann U, Webber K, Di Carlo A, Beers R, Chowdhury P, Chang K, Chaudhary V, Gallo M, Pastan I. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers.  Int J Cancer. 1997;  71 638-644
    CrossrefPubMedGoogle Scholar
  • 6 Buschard K, Brogren C H, Ropke C, Rygaard J. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2.  Apmis. 1988;  96 342-346
    PubMedGoogle Scholar
  • 7 Camera L, Kinuya S, Garmestani K, Pai L H, Brechbiel M W, Gansow O A, Paik C H, Pastan I, Carrasquillo J A. Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts.  Nucl Med Biol. 1993;  20 955-962
    PubMedGoogle Scholar
  • 8 Carter P, Kelley R F, Rodrigues M L, Snedecor B, Covarrubias M, Velligan M D, Wong W L, Rowland A M, Kotts C E, Carver M E. et al . High level Escherichia coli expression and production of a bivalent humanized antibody fragment.  Biotechnology (NY). 1992;  10 163-167
    PubMedGoogle Scholar
  • 9 Casey J L, Napier M P, King D J, Pedley R B, Chaplin L C, Weir N, Skelton L, Green A J, Hope-Stone L D, Yarranton G T, Begent R H. Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study.  Br J Cancer. 2002;  86 1401-1410
    CrossrefPubMedGoogle Scholar
  • 10 Colcher D, Bird R, Roselli M, Hardman K D, Johnson S, Pope S, Dodd S W, Pantoliano M W, Milenic D E, Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein.  J Natl Cancer Inst. 1990;  82 1191-1197
    PubMedGoogle Scholar
  • 11 Colcher D, Pavlinkova G, Beresford G, Booth B J, Choudhury A, Batra S K. Pharmacokinetics and biodistribution of genetically-engineered antibodies.  Q J Nucl Med. 1998;  42 225-241
    PubMedGoogle Scholar
  • 12 Covell D G, Barbet J, Holton O D, Black C D, Parker R J, Weinstein J N. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.  Cancer Res. 1986;  46 3969-3978
    PubMedGoogle Scholar
  • 13 DeNardo S J, Peng J S, DeNardo G L, Mills S L, Epstein A L. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development.  Int J Rad Appl Instrum B. 1986;  13 303-310
    PubMedGoogle Scholar
  • 14 Garnuszek P, Licinska I, Fiedor P, Mazurek A P. The synthesis, radioiodination and preliminary biological study of the new carboxylic derivatives of dithizone.  Appl Radiat Isot. 1998;  49 1563-1571
    CrossrefPubMedGoogle Scholar
  • 15 Hampe C S, Lundgren P, Daniels T L, Hammerle L P, Marcovina S M, Lernmark A. A novel monoclonal antibody specific for the N-terminal end of GAD65.  J Neuroimmunol. 2001;  113 63-71
    CrossrefPubMedGoogle Scholar
  • 16 Izard M E, Boniface G R, Hardiman K L, Brechbiel M W, Gansow O A, Walkers K Z. An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6- methyldiethylenetriaminepentaacetic acid.  Bioconjug Chem. 1992;  3 346-350
    CrossrefPubMedGoogle Scholar
  • 17 Kabat E A, Wu T T, Perry H M, Gottesman K, Foeller C. Sequences of Proteins of Immunological Interest. Washington, DC; Services US DoHaH 1991
    Google Scholar
  • 18 Konidaris C, Simonson W, Michelsen B, Papadopoulos G K. Specific monoclonal antibodies against the surface of rat islet beta cells.  Cell Biol Int. 2002;  26 817-828
    CrossrefPubMedGoogle Scholar
  • 19 Logsdon C D, Moessner J, Williams J A, Goldfine I D. Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells.  J Cell Biol. 1985;  100 1200-1208
    CrossrefPubMedGoogle Scholar
  • 20 Malaisse W J. On the track to the beta-cell.  Diabetologia. 2001;  44 393-406
    CrossrefPubMedGoogle Scholar
  • 21 Milenic D E, Yokota T, Filpula D R, Finkelman M A, Dodd S W, Wood J F, Whitlow M, Snoy P, Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.  Cancer Res. 1991;  51 6363-6371
    PubMedGoogle Scholar
  • 22 Moore A, Bonner-Weir S, Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes.  Diabetes. 2001;  50 2231-2236
    PubMedGoogle Scholar
  • 23 Mossner J, Logsdon C D, Williams J A, Goldfine I D. Insulin, via its own receptor, regulates growth and amylase synthesis in pancreatic acinar AR42J cells.  Diabetes. 1985;  34 891-897
    CrossrefPubMedGoogle Scholar
  • 24 Neidhardt F C, Bloch P L, Smith D F. Culture medium for enterobacteria.  J Bacteriol. 1974;  119 736-747
    PubMedGoogle Scholar
  • 25 Padoa C J, Banga J P, Madec A M, Ziegler M, Schlosser M, Ortqvist E, Kockum I, Palmer J, Rolandsson O, Binder K A, Foote J, Luo D, Hampe C S. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs.  Diabetes. 2003;  52 2689-2695
    PubMedGoogle Scholar
  • 26 Sweet I R, Cook D L, Lernmark A, Greenbaum C J, Krohn K A. Non-invasive imaging of beta cell mass: a quantitative analysis.  Diabetes Technol Ther. 2004 b;  6 652-659
    CrossrefPubMedGoogle Scholar
  • 27 Sweet I R, Cook D L, Lernmark A, Greenbaum C J, Wallen A R, Marcum E S, Stekhova S A, Krohn K A. Systematic screening of potential beta-cell imaging agents.  Biochem Biophys Res Commun. 2004 a;  314 976-983
    CrossrefPubMedGoogle Scholar
  • 28 Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.  Cancer Res. 1999;  59 347-352
    PubMedGoogle Scholar
  • 29 Yokota T, Milenic D E, Whitlow M, Wood J F, Hubert S L, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.  Cancer Res. 1993;  53 3776-3783
    PubMedGoogle Scholar
  • 30 Ziegler B, Lucke S, Kohler E, Hehmke B, Schlosser M, Witt S, Besch W, Ziegler M. Monoclonal antibody-mediated cytotoxicity against rat beta cells detected in vitro does not cause beta-cell destruction in vivo.  Diabetologia. 1992;  35 608-613
    CrossrefPubMedGoogle Scholar

Ian R. Sweet

University of Washington

1959 Pacific Street NE

K-165 Health Sciences Building

Seattle, WA 98195

USA

Phone: + 2066854775

Fax: + 20 65 43 31 69

Email: isweet@u.washington.edu

      >